TrialBlood2025

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.

Laurie H Sehn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.